Pharmaceutical News

RSS

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

The Drugs for Neglected Diseases Initiative now has the rights to "develop a class of potential anti-[tuberculosis] compounds" for the treatment of Chagas disease, African sleeping sickness and leishmaniasis, Reuters reports (Nebehay, 7/7).

8 Jul 2010

Olaparib shows promising results against inherited forms of breast and ovarian cancer

Olaparib, a new type of experimental drug called a PARP inhibitor, has shown promising results against inherited forms of breast and ovarian cancer in two small clinical trials led by scientists at the Breakthrough Breast Cancer Research Unit at King's College London.

8 Jul 2010

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

8 Jul 2010

Vitamin E may help prevent cognitive deterioration in elderly people: Study

High levels of several vitamin E components in the blood are associated with a decreased risk for Alzheimer's disease in advanced age, suggesting that vitamin E may help prevent cognitive deterioration in elderly people. This is the conclusion reached in a Swedish study published in the July 2010 issue of the Journal of Alzheimer's Disease.

8 Jul 2010

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled trial and is anticipated to begin later this summer.

8 Jul 2010

Winston submits NDA for CIVANEX to U.S. FDA

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee.

7 Jul 2010

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation for SBC-102, the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease, a condition for which there is currently no approved treatment.

7 Jul 2010

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Cipher Pharmaceuticals Inc. today announced that it reached a cumulative sales milestone for Lipofen, the Company's fenofibrate product. Achieving this target triggers a US$1.0 million milestone payment from Kowa Pharmaceuticals America Inc., Cipher's U.S. marketing and distribution partner, which will be reflected in Cipher's revenue for the second quarter of fiscal 2010.

7 Jul 2010

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

Commonly used painkillers like ibuprofen do not increase the risk of heart attack in the elderly population, according to a new study. Researchers found that the use of these drugs - also called non-steroidal anti-inflammatory drugs - was also associated with a lower risk of death although they are not sure why.

7 Jul 2010

CREW calls for antitrust investigation into drug companies

Today, Citizens for Responsibility and Ethics in Washington (CREW) sent a letter to the Federal Trade Commission (FTC) asking for an antitrust investigation into drug companies that offer significant discounts to doctors for providing patients with only that company's vaccines. CREW sent its letter after learning that Sanofi Pasteur and Merck require physician healthcare groups purchasing their vaccines to enter into contracts prohibiting them from purchasing vaccines made by other companies.

7 Jul 2010

ASPREE study aims to assess health benefits of aspirin

In an effort to extend the length of a disability-free life for older adults, researchers from Rush University Medical Center are partnering with colleagues from across the U.S. and Australia in the largest international trial ever sponsored by the National Institute on Aging.

7 Jul 2010

European Commission approves new indication for ORENCIA in combination with MTX for RA

Bristol-Myers Squibb Company has today announced that on 1 July 2010 the European Commission approved a new indication for ORENCIA® (abatacept), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor.

7 Jul 2010

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

A treatment plan used to prevent potentially dangerous blood clots in recovering surgical patients can also benefit some patients immobilized by acute medical illness, doctors have found in a multi-institutional study.

7 Jul 2010

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

When ordinary over-the-counter laxatives fail to work, doctors turn to other medications to treat people with constipation. Now, a new review of existing research finds that one common drug treatment is better than another is at helping patients who are desperate to get things moving.

7 Jul 2010

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.

7 Jul 2010

Retin-A Micro Pump combines tretinoin for treating acne: Study

From the minute they wake until the minute they sleep, today's teenagers have busy, demanding schedules. Life may be hectic, but an acne care routine doesn't have to get in the way, according to a new study published in the July 2010 issue of Journal of Drugs in Dermatology.

7 Jul 2010

Apicore files DMF for Fondaparinux Sodium API with U.S. FDA

Apicore LLC announced today that they filed a drug master file (DMF) for Fondaparinux Sodium active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) on June 28, 2010.

7 Jul 2010

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Caraco Pharmaceutical Laboratories, Ltd. has started shipping azelastine ophthalmic solution, 0.05%. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA).

7 Jul 2010

FDA approves Glassia for treating Alpha 1 deficiency

Kamada, today announced that the United States Food and Drug Administration has approved Glassia (Alpha 1 Proteinase inhibitor, also known as Alpha-1-Antitrypsin) for the treatment of Alpha 1 deficiency. GlassiaM is now the first and only liquid Alpha- 1-Proteinase Inhibitor worldwide available liquid, ready to use, Alpha- 1-Proteinase Inhibitor on the market.

7 Jul 2010

Pharmaceutical News

Drug initiative granted rights to develop TB compounds for potential treatment of NTDs

Olaparib shows promising results against inherited forms of breast and ovarian cancer

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

Vitamin E may help prevent cognitive deterioration in elderly people: Study

FDA approves Beech Tree Labs' IND for Phase 1/2a clinical evaluation of BTL-TML-HSV

Winston submits NDA for CIVANEX to U.S. FDA

FDA grants orphan drug designation for Synageva BioPharma's SBC-102

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Use of NSAIDs do not increase risk of heart attack in elderly patients: Study

CREW calls for antitrust investigation into drug companies

ASPREE study aims to assess health benefits of aspirin

European Commission approves new indication for ORENCIA in combination with MTX for RA

Extended treatment with blood thinner benefits patients immobilized by acute medical illness: Study

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

Retin-A Micro Pump combines tretinoin for treating acne: Study

Apicore files DMF for Fondaparinux Sodium API with U.S. FDA

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

FDA approves Glassia for treating Alpha 1 deficiency

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News